NZ279238A - Microgranules containing 5-nitro-imidazole derivatives, mixtures of gastroresistant and prolonged-release microgranules, and medicaments thereof - Google Patents
Microgranules containing 5-nitro-imidazole derivatives, mixtures of gastroresistant and prolonged-release microgranules, and medicaments thereofInfo
- Publication number
- NZ279238A NZ279238A NZ279238A NZ27923895A NZ279238A NZ 279238 A NZ279238 A NZ 279238A NZ 279238 A NZ279238 A NZ 279238A NZ 27923895 A NZ27923895 A NZ 27923895A NZ 279238 A NZ279238 A NZ 279238A
- Authority
- NZ
- New Zealand
- Prior art keywords
- microgranules
- prolonged
- form according
- release
- galenic form
- Prior art date
Links
- 230000002035 prolonged effect Effects 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims description 30
- 150000004958 5-nitroimidazoles Chemical class 0.000 title claims description 21
- 239000003814 drug Substances 0.000 title 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 9
- 230000007935 neutral effect Effects 0.000 claims description 16
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 14
- 238000004090 dissolution Methods 0.000 claims description 13
- 229960000282 metronidazole Drugs 0.000 claims description 13
- 239000000454 talc Substances 0.000 claims description 13
- 229910052623 talc Inorganic materials 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 239000004531 microgranule Substances 0.000 claims description 8
- 208000004881 Amebiasis Diseases 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 230000001079 digestive effect Effects 0.000 claims description 5
- 229960004076 secnidazole Drugs 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 241000589989 Helicobacter Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims description 2
- 229940127555 combination product Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229960005053 tinidazole Drugs 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 16
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 12
- 210000000936 intestine Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 206010001980 Amoebiasis Diseases 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000001069 triethyl citrate Substances 0.000 description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 5
- 235000013769 triethyl citrate Nutrition 0.000 description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229940063190 flagyl Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- VYDWQPKRHOGLPA-UHFFFAOYSA-N 5-nitroimidazole Chemical compound [O-][N+](=O)C1=CN=CN1 VYDWQPKRHOGLPA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- -1 Hydroxypropoxy groups Chemical group 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241001314546 Microtis <orchid> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical class O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9400394A FR2715067B1 (fr) | 1994-01-14 | 1994-01-14 | Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal. |
| PCT/FR1995/000039 WO1995019168A1 (fr) | 1994-01-14 | 1995-01-12 | Microgranules de derives de 5-nitro imidazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ279238A true NZ279238A (en) | 1998-03-25 |
Family
ID=9459066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ279238A NZ279238A (en) | 1994-01-14 | 1995-01-12 | Microgranules containing 5-nitro-imidazole derivatives, mixtures of gastroresistant and prolonged-release microgranules, and medicaments thereof |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPH09507499A (cs) |
| KR (1) | KR100320140B1 (cs) |
| CN (1) | CN1088357C (cs) |
| AT (1) | ATE187068T1 (cs) |
| AU (1) | AU705570B2 (cs) |
| BR (1) | BR9506507A (cs) |
| CZ (1) | CZ286080B6 (cs) |
| DE (1) | DE69513632T2 (cs) |
| DK (1) | DK0739201T3 (cs) |
| ES (1) | ES2139883T3 (cs) |
| MA (1) | MA23429A1 (cs) |
| MX (1) | MX9602772A (cs) |
| NZ (1) | NZ279238A (cs) |
| OA (1) | OA10583A (cs) |
| PL (1) | PL178424B1 (cs) |
| PT (1) | PT739201E (cs) |
| RU (1) | RU2152212C1 (cs) |
| SK (1) | SK282066B6 (cs) |
| UA (1) | UA28031C2 (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4331930B2 (ja) * | 2001-10-17 | 2009-09-16 | 武田薬品工業株式会社 | 酸に不安定な薬物の高含量顆粒 |
| RU2220711C1 (ru) * | 2002-04-24 | 2004-01-10 | Закрытое акционерное общество "Брынцалов-А" | Противомикробное и противопротозойное средство "трихоброл" |
| AU2015311674B2 (en) | 2014-09-05 | 2018-03-08 | Evofem Biosciences, Inc. | Secnidazole for use in the treatment of bacterial vaginosis |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346095A (en) * | 1978-02-10 | 1982-08-24 | Mercer James B | Therapeutic treatment for viral hepatitis infection |
| US5256684A (en) * | 1985-06-13 | 1993-10-26 | The Procter & Gamble Company | Methods and compositions for the treatment of gastrointestinal disorders |
| DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| AU7909691A (en) * | 1990-05-14 | 1991-12-10 | Gary R. Jernberg | Surgical implant and method incorporating chemotherapeutic agents |
| FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
-
1995
- 1995-01-12 DK DK95907683T patent/DK0739201T3/da active
- 1995-01-12 SK SK914-96A patent/SK282066B6/sk unknown
- 1995-01-12 PL PL95315530A patent/PL178424B1/pl not_active IP Right Cessation
- 1995-01-12 NZ NZ279238A patent/NZ279238A/en unknown
- 1995-01-12 ES ES95907683T patent/ES2139883T3/es not_active Expired - Lifetime
- 1995-01-12 MX MX9602772A patent/MX9602772A/es not_active IP Right Cessation
- 1995-01-12 RU RU96117257/14A patent/RU2152212C1/ru not_active IP Right Cessation
- 1995-01-12 DE DE69513632T patent/DE69513632T2/de not_active Expired - Fee Related
- 1995-01-12 CN CN95191222A patent/CN1088357C/zh not_active Expired - Fee Related
- 1995-01-12 AU AU15803/95A patent/AU705570B2/en not_active Ceased
- 1995-01-12 PT PT95907683T patent/PT739201E/pt unknown
- 1995-01-12 BR BR9506507A patent/BR9506507A/pt not_active IP Right Cessation
- 1995-01-12 KR KR1019960703797A patent/KR100320140B1/ko not_active Expired - Fee Related
- 1995-01-12 AT AT95907683T patent/ATE187068T1/de not_active IP Right Cessation
- 1995-01-12 JP JP7518878A patent/JPH09507499A/ja active Pending
- 1995-01-12 CZ CZ19962055A patent/CZ286080B6/cs not_active IP Right Cessation
- 1995-01-12 UA UA96083232A patent/UA28031C2/uk unknown
- 1995-01-13 MA MA23756A patent/MA23429A1/fr unknown
-
1996
- 1996-07-12 OA OA60863A patent/OA10583A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK282066B6 (sk) | 2001-10-08 |
| DK0739201T3 (da) | 2000-05-01 |
| MX9602772A (es) | 1997-05-31 |
| BR9506507A (pt) | 1997-09-09 |
| KR100320140B1 (ko) | 2002-07-02 |
| AU1580395A (en) | 1995-08-01 |
| RU2152212C1 (ru) | 2000-07-10 |
| UA28031C2 (uk) | 2000-10-16 |
| CZ286080B6 (cs) | 2000-01-12 |
| PT739201E (pt) | 2000-05-31 |
| CN1088357C (zh) | 2002-07-31 |
| CZ205596A3 (en) | 1996-10-16 |
| OA10583A (en) | 2002-07-10 |
| MA23429A1 (fr) | 1995-10-01 |
| PL315530A1 (en) | 1996-11-12 |
| SK91496A3 (en) | 1996-12-04 |
| AU705570B2 (en) | 1999-05-27 |
| ATE187068T1 (de) | 1999-12-15 |
| DE69513632T2 (de) | 2000-04-06 |
| DE69513632D1 (de) | 2000-01-05 |
| PL178424B1 (pl) | 2000-04-28 |
| CN1138826A (zh) | 1996-12-25 |
| JPH09507499A (ja) | 1997-07-29 |
| ES2139883T3 (es) | 2000-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2681315C2 (ru) | Лекарственные формы для пероральной доставки адсорбентов в кишечник | |
| TW576743B (en) | Extended release formulations of erythromycin derivatives | |
| CA2041400C (en) | Preparation of a medicament | |
| AU774099B2 (en) | Controlled release compositions comprising nimesulide | |
| JP3725542B2 (ja) | ピコサルフェート剤形 | |
| BRPI0608853B1 (pt) | composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes | |
| TW201041607A (en) | Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics | |
| JP2000514051A (ja) | ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法 | |
| JP2002080398A (ja) | ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物 | |
| JP2009543791A (ja) | 即放性形態および徐放性形態のトラマドールを有するマルチパーティキュレート処方物 | |
| CN108348475A (zh) | 处于液体剂型的多层药学活性化合物释放微粒 | |
| CN109893516A (zh) | 用于治疗幽门螺杆菌的药物组合物 | |
| US20060159758A1 (en) | Coating composition for taste masking coating and methods for their application and use | |
| CN102639123A (zh) | 药物固体剂型 | |
| CH675537A5 (cs) | ||
| US5549911A (en) | Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract | |
| JPS63258809A (ja) | 医薬活性成分の放出性にすぐれ、かつ苦味を隠蔽した細粒剤 | |
| EP2386302A1 (en) | A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof | |
| NZ279238A (en) | Microgranules containing 5-nitro-imidazole derivatives, mixtures of gastroresistant and prolonged-release microgranules, and medicaments thereof | |
| CZ20032488A3 (cs) | Gastroirezistentní soli ketokyselin a aminikyselin a jejich použití pro přípravu léků | |
| CA2180837C (fr) | Microgranules de derives de 5-nitro imidazole | |
| US20230398102A1 (en) | Rifaximin liquid formulations for use inthe treatment of sickle cell disease | |
| JPS61137813A (ja) | 持続性セフラジン製剤 | |
| JPWO2003075918A1 (ja) | 塩酸ピルジカイニド含有錠剤（湿式） | |
| EP4433034A1 (en) | Controlled release formulations of flavoxate and process for preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |